Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial
Open Access
- 2 June 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 7196-7206
Abstract
Aims: This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods: Participants were randomised to receive the long‐acting GIP receptor agonist macupatide, dulaglutide or both combined. Insulin sensitivity ( M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12‐week treatment. Results: Overall baseline means were cDI, 0.3 pmol*m −2 *L*min −2 *kg −1 ; M value, 5.8 mg*kg −1 *min −1 ; ISR, 116.8 pmol*min −1 *m −2 . The 12‐week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%). Macupatide alone significantly increased the M value and, to a lesser yet significant extent, ISR. Combination therapy was numerically greater than both monotherapies in augmenting all indices. The most frequent adverse events were injection site reactions and diarrhoea. Study discontinuations due to treatment‐emergent adverse events were uncommon. There were no deaths during the study. Conclusion: These findings demonstrate that chronic GIP receptor activation in individuals with T2D leads primarily to increased insulin sensitivity, and that combining GIP and GLP‐1 receptor agonism can augment both insulin secretion and insulin sensitivity compared to GLP‐1 therapy alone.Keywords
Funding Information
- Eli Lilly and Company (LY3532226)
This publication has 19 references indexed in Scilit:
- Tirzepatide as Compared with Semaglutide for the Treatment of ObesityNew England Journal of Medicine, 2025
- Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparisonDiabetes, Obesity and Metabolism, 2025
- Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysisDiabetes, Obesity and Metabolism, 2025
- A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapyDiabetes, Obesity and Metabolism, 2024
- Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptorCell Metabolism, 2024
- Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activationMolecular Metabolism, 2021
- GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese miceJournal of Clinical Investigation, 2021
- Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial functionMetabolism, 2017
- Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined HyperlipidemiaJACC, 2007
- Glucose clamp technique: a method for quantifying insulin secretion and resistance.American Journal of Physiology-Endocrinology and Metabolism, 1979